Skip to main content
  • About Us
  • Image Credits
  • Contributor Info
  • RSS
  • Log In
  • Join
  • TwitterTwitter
  • E-Alerts
  • Visit StemJournal

Main menu

  • About
    • Image Credits
    • Contributor Info
    • E-Alerts
  • Chapters
    • Cellular and nuclear reprogramming
    • Ectoderm specification and differentiation
    • Endoderm specification and differentiation
    • Epigenetics
    • Genomics and proteomics
    • Germ cell and somatic stem cell biology in reproduction
    • Manufacturing
    • Mesoderm specification and differentiation
    • Niche biology, homing, and migration
    • Renewal
    • Stem cell immunology
    • Therapeutic prospects
    • Tissue engineering
  • Protocols
    • Ectoderm differentiation
    • Endoderm differentiation
    • Genome editing
    • Mesoderm differentiation
    • Pluripotent stem cells
    • PSC characterization
    • PSC genetic stability
    • Reprogramming
  • Stem Cell COREdinates
    • Core Facility Profiles
      • Boston Children's Hospital Human Neuron Core
      • Boston University Center for Regenerative Medicine iPSC Core
      • Columbia Stem Cell Initiative Stem Cell Core Facility
      • Harvard Stem Cell Institute iPS Core Facility
    • Other Resources
  • News & Commentaries
    • Latest News
  • Journal Stream
  • Forum

    Search form

    You are here

    Home

    Biblio

    Author Title Type [ Year(Asc)]
    Filters: Author is Cattaneo, Chiara  [Clear All Filters]
    2020
    Ferreri AJM, Cattaneo C, Lleshi A, Verga L, Allione B, Facchetti F, Ponzoni M, Foppoli M, Ferrari D, Rigacci L, et al. A dose-dense short-term therapy for human immunodeficiency virus/acquired immunodeficiency syndrome patients with high-risk Burkitt lymphoma or high-grade B-cell lymphoma: safety and efficacy results of the "CARMEN" phase II trial. Br J Haematol. 2020.
    • PubMed
    • Google Scholar
    Borlenghi E, Cattaneo C, Cerqui E, Archetti S, Bertoli D, Bellotti D, Gramegna D, Soverini G, Oberti M, Schieppati F, et al. Post-remission Therapy with Repeated Courses of High Dose Cytarabine, Idarubicin and Limited Autologous Stem Cell Support Achieves a Very Good Long-Term Outcome in ELN Favorable and Intermediate-Risk AML. Hematol Oncol. 2020.
    • PubMed
    • Google Scholar
    2019
    Trecarichi EMaria, Giuliano G, Cattaneo C, Ballanti S, Criscuolo M, Candoni A, Marchesi F, Laurino M, Dargenio M, Fanci R, et al. Bloodstream infections caused by Escherichia coli in onco-haematological patients: Risk factors and mortality in an Italian prospective survey. PLoS One. 2019;14(10):e0224465.
    • PubMed
    • Google Scholar

    Disclaimer | Privacy Policy | StemBook is published by IOS Press, Copyright © 2019
    Copyright 2013 by the Massachusetts General Hospital. Some sections copyright 2008–2009 by The President and Fellows of Harvard College.

    IOS Press logoHSCI logoNIH logoMIND logo


    Creative Commons License
    All content unless otherwise noted is licensed under a Creative Commons Attribution 3.0 Unported License